Immuno-oncology targeting Human Endogenous Retroviruses (HERVs)
| Date | Round | Amount |
|---|---|---|
| May 2023 | Seed Copenhagen biotech InProTher raised EUR6M seed for its HERV-targeting cancer immunotherapy. | $6.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.